Obermatt

Whanin Pharm

KSC:016580 · KR7016580003
PharmaceuticalsSmall

360

99
EV / EBIT70
Price / Owner Earnings18
Owner Earnings Yield98
Dividend Yield93
Price/Sales77
EV / Gross Profit78
Price/Book100
Return on Capital76
Cash Return on Capital81
Return on Equity77
EBIT Margin72
Gross Profitability45
Cash Conversion13
Accruals27
Owner Earnings Margin94
Sales growth46
Profit Growth29
Long-Term EPS Growth95
Owner Earnings Growth67
Reinvestment17
Price momentum57
Debt load95
Refinancing80
Debt Payback100
Liquidity100
Analyst ratings100
Opinion Changes50
Price Target Upside46
Market mood1
Value Creation8/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Whanin Pharm clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeKOSE
Founded1982
Websitewhanin.com
ISINKR7016580003
Last UpdateApr 2, 2026
Themes
Chronic DiseasesUrologyPsychiatryOsteoporosisNeurologyCentral Nervous SystemInflammationCardiovascular

Description

Analysis

Middle-of-the-road

Whan In Pharm Co.,Ltd. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group. One caution: reported profits have recently run ahead of actual cash, which we track closely.

The price is attractive. You pay 7.4× its owner earnings: the cash an owner could take out each year, which is in the historically attractive zone. At today's price, the market is assuming roughly -7% yearly growth; analysts expect 25%. The price, in other words, assumes less than the experts do.

The trajectory is solid and the balance sheet is sturdy. The company scores 8/20 on our value-creation score: creating some value.

What to watch: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
94
2026

All-time high

98

Mar 2026

All-time low

94

Jun 2026

Average rank

96

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
77
Price/Earnings
78
Price/Book
100
Dividend Yield
93
Value (overall)
100

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Whanin Pharm with its peers
Yungjin Pharm
KSC:003520
34
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Samil Pharmaceutical
KSC:000520
28
CountrySouth Korea
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →
Hana Pharm
KSC:293480
88
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Dongwha Pharm
KSC:000020
44
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Ildong Holdings
KSC:000230
83
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Chongkundang Holdings
KSC:001630
56
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →